Additionally, few trials have directly compared ACE inhibitors with ARBs in homogeneous CKD subgroups, and the role of adjunctive therapies, such as potassium binders to enable more aggressive RAAS blockade, remains incompletely explored outside of small targeted studies. Here, ACE is linked to chronic kidney disease.